Iridex Q1 2023 revenue $13.7M (+2% YoY), net loss narrows to $2.1M

IRIDEX CORP

2023-Q1 EPS reported -$0.13 revenue$13,706,000

Cyclo G6 revenue $3.7M (+4% YoY); 61 systems sold vs 56 a year ago.
Retina product revenue flat at $7.2M; gross margin fell to 43.3% from 44.6%.
Net loss of $2.1M ($0.13/sh) vs $2.4M ($0.15/sh); cash $11.0M.
FY2023 guidance reaffirmed: revenue $57-59M, Cyclo G6 probes 65k-67k.
FDA clearance received in February for new single-spot 532/577 laser platform.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRIDEX CORP reported first quarter ended April 1, 2023 results: revenue $13.7 million, net income $2.1 million, EPS $0.13 per share.

Period: first quarter ended April 1, 2023
Revenue: $13.7 million
Net income: $2.1 million
EPS: $0.13 per share
Result: reported results

Exact text from the filing

Revenue for the three months ended April 1, 2023 was $13.7 million compared to $13.4 million during the same period of the prior year.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

IRIDEX CORP reported full year 2023 results: revenue $57 million to $59 million. Guidance reaffirmed.

Period: full year 2023
Revenue: $57 million to $59 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

Total revenue for the full year is expected to be $57 million to $59 million.

View on SEC.gov

Browse all earnings releases →

IRIDEX CORP filing history →

Source: SEC EDGAR

accession 0000950170-23-021241

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.